Global Genetic Testing Market- Industry Trends and Forecast to 2031

List of Tables

Global genetic testing market is expected to reach USD 62,607,580.19 thousand by 2031 from USD 18,810,536.39 thousand in 2023, growing at a CAGR of 16.5% during the forecast period of 2024 to 2031.

Market Segmentation

Global Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.

Overview of Global Genetic Testing Market Dynamics

Driver
Growing prevalence of genetic disorders
Restrain
High cost of genetic testing
Opportunity
Strategic initiatives by the key market player

Market Players

Some of the key market players for global genetic testing market are:

Thermo Fisher Scientific Inc.
Invitae Corporation
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Fulgent Genetics
Myriad Genetics, Inc.
Abbott
Eurofins Scientific
Sorenson Genomics
BIO-HELIX
Biocartis
Cepheid (A subsidiary of Danaher)
PacBio
ELITechGroup
Genes2Me
Eugene Labs
Otogenetics
Mapmygenome
MedGenome
BioReference
Natera, Inc.

1 INTRODUCTION 68

1.1 OBJECTIVES OF THE STUDY 68
1.2 MARKET DEFINITION 68
1.3 OVERVIEW OF THE GLOBAL GENETIC TESTING MARKET 68
1.4 LIMITATIONS 70
1.5 MARKETS COVERED 70

2 MARKET SEGMENTATION 73

2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 CURRENCY AND PRICING 75
2.5 DBMR TRIPOD DATA VALIDATION MODEL 76
2.6 TYPE LIFELINE CURVE 80
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81
2.8 DBMR MARKET POSITION GRID 82
2.9 MARKET APPLICATION COVERAGE GRID 83
2.10 VENDOR SHARE ANALYSIS 84
2.11 SECONDARY SOURCES 85
2.12 ASSUMPTIONS 85

3 EXECUTIVE SUMMARY 86

4 PREMIUM INSIGHTS 88

4.1 PESTAL ANALYSIS 91
4.2 PORTERS 5 FORCES 92
4.3 EPIDEMIOLOGY 93

5 GLOBAL GENETIC TESTING MARKET: REGULATIONS 94

6 MARKET OVERVIEW 96

6.1 DRIVERS 98
- 6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 98
- 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 98
- 6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 99
- 6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 99
6.2 RESTRAINTS 100
- 6.2.1 HIGH COST OF GENETIC TESTING 100
- 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 101
6.3 OPPORTUNITIES 101
- 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 101
- 6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 102
- 6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 102
6.4 CHALLENGES 103
- 6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 103
- 6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 104

7 GLOBAL GENETIC TESTING MARKET, BY TYPE 105

7.1 OVERVIEW 106
7.2 DIAGNOSTIC TESTING 110
7.3 PRENATAL TESTING 110
- 7.3.1 NON-INVASIVE SCREENING 111
  - 7.3.1.1 WHOLE GENOME SEQUENCING 112
  - 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 112
  - 7.3.1.3 OTHERS 112
- 7.3.2 BY CONDITION 113
  - 7.3.2.1 TRISOMY 21 113
  - 7.3.2.2 KLINEFELTER SYNDROME 113
  - 7.3.2.3 JACOBS SYNDROME 113
  - 7.3.2.4 CYSTIC FIBROSIS 113
  - 7.3.2.5 TURNER SYNDROME 114
  - 7.3.2.6 TRISOMY 18 114
  - 7.3.2.7 HEMOPHILIA 114
  - 7.3.2.8 TRISOMY 13 114
  - 7.3.2.9 MICRODELETION SYNDROME 114
  - 7.3.2.10 FETAL GENDER 114
  - 7.3.2.11 OTHERS 114
- 7.3.3 BY SCREENING TYPE 115
  - 7.3.3.1 CARRIER SEQUENCING 115
  - 7.3.3.2 SEQUENTIAL SEQUENCING 115
- 7.3.4 MATERNAL SERUM QUAD SCREENING 115
7.4 NEW-BORN SCREENING 116
- 7.4.1 SICKLE CELL DISEASE 116
- 7.4.2 CONGENITAL HYPOTHYROIDISM 117
- 7.4.3 PHENYLKETONURINA (PKU) 117
- 7.4.4 GALACTOSEMIA 117
- 7.4.5 MAPLE SYRUP URINE DISEASE 117
- 7.4.6 OTHERS 117
7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 117
7.6 CARRIER TESTING 118
- 7.6.1 MOLECULAR SCREENING TEST 118
- 7.6.2 BIOCHEMICAL SCREENING TEST 119
  - 7.6.2.1 EXPANDED CARRIER SCREENING 119
  - 7.6.2.2 PREDESIGNED PANEL TESTING 120
  - 7.6.2.3 CUSTOM-MADE PANEL TESTING 120
  - 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 120
    - 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 120
    - 7.6.2.4.2 PULMONARY CONDITIONS 121
    - 7.6.2.4.3 NEUROLOGICAL CONDITIONS 121
    - 7.6.2.4.4 OTHER CONDITIONS 121
7.7 OTHER TYPES 121

8 GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY 122

8.1 OVERVIEW 123
8.2 POLYMERASE CHAIN REACTION 126
- 8.2.1 REAL-TIME PCR (QPCR) 127
- 8.2.2 DIGITAL PCR (DPCR) 127
- 8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 127
- 8.2.4 HOT-START PCR 127
- 8.2.5 MULTIPLEX PCR 127
- 8.2.6 OTHER PCR 127
8.3 DNA SEQUENCING (NGS-BASED TESTING) 128
- 8.3.1 NEXT GENERATION SEQUENCING (NGS) 128
- 8.3.2 SANGER SEQUENCING (SINGLE GENE) 128
- 8.3.3 OTHER 129
8.4 WHOLE GENOME SEQUENCING 129
8.5 MICROARRAYS 129
- 8.5.1 DNA MICROARRAYS 130
- 8.5.2 PROTEIN MICROARRAYS 130
- 8.5.3 OTHER MICROARRAYS 130
8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 130
8.7 OTHERS 131

9 GLOBAL GENETIC TESTING MARKET, BY DISEASES 132

9.1 OVERVIEW 133
9.2 CANCER 136
- 9.2.1 BREAST 137
- 9.2.2 COLON 137
- 9.2.3 LUNG 137
- 9.2.4 PROSTATE 137
- 9.2.5 OTHERS 137
9.3 SICKLE CELL ANEMIA 138
9.4 THALASSEMIA 138
9.5 RARE GENETIC DISORDER 139
- 9.5.1 TRISOMY 21 139
- 9.5.2 MONOSOMY X 139
- 9.5.3 TRISOMY 13 140
- 9.5.4 MICRODELETION SYNDROME 140
- 9.5.5 TRISOMY 18 140
- 9.5.6 OTHERS 140
9.6 FRAGILE X SYNDROME 140
9.7 DUCHENNE MUSCULAR DYSTROPHY 141
9.8 HUNTINGTON'S DISEASE 141
9.9 CYSTIC FIBROSIS 142
9.10 OTHERS 142

10 GLOBAL GENETIC TESTING MARKET, BY END USER 143

10.1 OVERVIEW 144
10.2 HOSPITALS 147
10.3 CLINICS 148
10.4 DIAGNOSTIC CENTERS 148
10.5 PRIVATE CLINICS 149
10.6 LABORATORY SERVICE PROVIDERS 149
10.7 PRIVATE LABORATORIES 150

11 GLOBAL GENETIC TESTING MARKET, BY REGION 151

11.1 OVERVIEW 152
11.2 NORTH AMERICA 155
- 11.2.1 U.S. 165
- 11.2.2 CANADA 176
- 11.2.3 MEXICO 187
11.3 EUROPE 198
- 11.3.1 GERMANY 207
- 11.3.2 FRANCE 218
- 11.3.3 U.K. 229
- 11.3.4 RUSSIA 240
- 11.3.5 ITALY 251
- 11.3.6 SPAIN 261
- 11.3.7 TURKEY 272
- 11.3.8 NETHERLANDS 283
- 11.3.9 SWITZERLAND 294
- 11.3.10 BELGIUM 305
- 11.3.11 REST OF EUROPE 316
11.4 ASIA-PACIFIC 317
- 11.4.1 CHINA 326
- 11.4.2 JAPAN 337
- 11.4.3 INDIA 348
- 11.4.4 SOUTH KOREA 359
- 11.4.5 AUSTRALIA 370
- 11.4.6 SINAGPORE 381
- 11.4.7 THAILAND 392
- 11.4.8 INDONESIA 403
- 11.4.9 PHILIPPINES 414
- 11.4.10 MALAYSIA 425
- 11.4.11 VIETNAM 436
- 11.4.12 REST OF ASIA-PACIFIC 447
11.5 SOUTH AMERICA 448
- 11.5.1 BRAZIL 456
- 11.5.2 ARGENTINA 466
- 11.5.3 REST OF SOUTH AMERICA 477
11.6 MIDDLE EAST AND AFRICA 478
- 11.6.1 SOUTH AFRICA 488
- 11.6.2 SAUDI ARABIA 499
- 11.6.3 U.A.E. 510
- 11.6.4 ISRAEL 521
- 11.6.5 EGYPT 532
- 11.6.6 REST OF MIDDLE EAST AND AFRICA 543

12 GLOBAL GENETIC TESTING MARKET, COMPANY LANDSCAPE 544

12.1 COMPANY SHARE ANALYSIS: GLOBAL 544

13 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 545

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 545

14 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE 546

14.1 COMPANY SHARE ANALYSIS: EUROPE 546

15 ASIA-PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 547

15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 547

16 SWOT ANALYSIS 548

17 COMPANY PROFILES 549

17.1 ILLUMINA, INC. 549
- 17.1.1 COMPANY SNAPSHOT 549
- 17.1.2 REVENUE ANALYSIS 549
- 17.1.3 COMPANY SHARE ANALYSIS 550
- 17.1.4 PRODUCT PORTFOLIO 550
- 17.1.5 RECENT DEVELOPMENT 551
17.2 CEPHEID 552
- 17.2.1 COMPANY SNAPSHOT 552
- 17.2.2 REVENUE ANALYSIS 552
- 17.2.3 COMPANY SHARE ANALYSIS 553
- 17.2.4 PRODUCT PORTFOLIO 553
- 17.2.5 RECENT DEVELOPMENT 553
17.3 FULGENT GENETICS 554
- 17.3.1 COMPANY SNAPSHOT 554
- 17.3.2 REVENUE ANALYSIS 554
- 17.3.3 COMPANY SHARE ANALYSIS 555
- 17.3.4 PRODUCT PORTFOLIO 555
- 17.3.5 RECENT DEVELOPMENT 556
17.4 PERKINELMER INC. 557
- 17.4.1 COMPANY SNAPSHOT 557
- 17.4.2 REVENUE ANALYSIS 557
- 17.4.3 COMPANY SHARE ANALYSIS 558
- 17.4.4 PRODUCT PORTFOLIO 558
- 17.4.5 RECENT DEVELOPMENT 558
17.5 THERMO FISHER SCIENTIFIC INC. 559
- 17.5.1 COMPANY SNAPSHOT 559
- 17.5.2 REVENUE ANALYSIS 559
- 17.5.3 COMPANY SHARE ANALYSIS 560
- 17.5.4 PRODUCT PORTFOLIO 560
- 17.5.5 RECENT DEVELOPMENT 561
  - 17.5.5.1 COLLABORATION 561
17.6 BIOREFERENCE 562
- 17.6.1 COMPANY SNAPSHOT 562
- 17.6.2 REVENUE ANALYSIS 562
- 17.6.3 PRODUCT PORTFOLIO 563
- 17.6.4 RECENT DEVELOPMENT 563
17.7 ELITECHGROUP 564
- 17.7.1 COMPANY SNAPSHOT 564
- 17.7.2 PRODUCT PORTFOLIO 564
- 17.7.3 RECENT DEVELOPMENTS 565
17.8 EUROFINS SCIENTIFIC 566
- 17.8.1 COMPANY SNAPSHOT 566
- 17.8.2 REVENUE ANALYSIS 566
- 17.8.3 PRODUCT PORTFOLIO 567
- 17.8.4 RECENT DEVELOPMENT 567
17.9 INVITAE CORPORATION 568
- 17.9.1 COMPANY SNAPSHOT 568
- 17.9.2 REVENUE ANALYSIS 568
- 17.9.3 PRODUCT PORTFOLIO 569
- 17.9.4 RECENT DEVELOPMENTS 569
17.10 MYRIAD GENETICS 570
- 17.10.1 COMPANY SNAPSHOT 570
- 17.10.2 REVENUE ANALYSIS 570
- 17.10.3 PRODUCT PORTFOLIO 571
- 17.10.4 RECENT DEVELOPMENT 571
17.11 ABBOTT 572
- 17.11.1 COMPANY SNAPSHOT 572
- 17.11.2 REVENUE ANALYSIS 572
- 17.11.3 PRODUCT PORTFOLIO 573
- 17.11.4 RECENT DEVELOPMENT 573
17.12 BIOCARTIS 574
- 17.12.1 COMPANY SNAPSHOT 574
- 17.12.2 REVENUE ANALYSIS 574
- 17.12.3 PRODUCT PORTFOLIO 575
- 17.12.4 RECENT DEVELOPMENTS 575
  - 17.12.4.1 PARTNERSHIP 575

17.13 BIO-HELIX 576
- 17.13.1 COMPANY SNAPSHOT 576
- 17.13.2 PRODUCT PORTFOLIO 576
- 17.13.3 RECENT DEVELOPMENT 576
17.14 BIO-RAD LABORATORIES, INC. 577
- 17.14.1 COMPANY SNAPSHOT 577
- 17.14.2 REVENUE ANALYSIS 577
- 17.14.3 PRODUCT PORTFOLIO 578
- 17.14.4 RECENT DEVELOPMENTS 578
17.15 EUGENE LABS 579
- 17.15.1 COMPANY SNAPSHOT 579
- 17.15.2 PRODUCT PORTFOLIO 579
- 17.15.3 RECENT DEVELOPMENT 579
17.16 F. HOFFMANN-LA ROCHE LTD 580
- 17.16.1 COMPANY SNAPSHOT 580
- 17.16.2 REVENUE ANALYSIS (PARENT COMPANY) 580
- 17.16.3 PRODUCT PORTFOLIO 581
- 17.16.4 RECENT DEVELOPMENT 581
17.17 GENES2ME 582
- 17.17.1 COMPANY SNAPSHOT 582
- 17.17.2 PRODUCT PORTFOLIO 582
- 17.17.3 RECENT DEVELOPMENT 582
17.18 MAPMYGENOME 583
- 17.18.1 COMPANY SNAPSHOT 583
- 17.18.2 PRODUCT PORTFOLIO 583
- 17.18.3 RECENT DEVELOPMENT 584
17.19 MEDGENOME 585
- 17.19.1 COMPANY SNAPSHOT 585
- 17.19.2 PRODUCT PORTFOLIO 585
- 17.19.3 RECENT DEVELOPMENT 586
17.20 NATERA, INC. 587
- 17.20.1 COMPANY SNAPSHOT 587
- 17.20.2 REVENUE ANALYSIS 587
- 17.20.3 PRODUCT PORTFOLIO 588
- 17.20.4 RECENT DEVELOPMENT 589
17.21 OTOGENETICS 590
- 17.21.1 COMPANY SNAPSHOT 590
- 17.21.2 PRODUCT PORTFOLIO 591
- 17.21.3 RECENT DEVELOPMENT 591

17.22 PACBIO 592
- 17.22.1 COMPANY SNAPSHOT 592
- 17.22.2 REVENUE ANALYSIS 592
- 17.22.3 PRODUCT PORTFOLIO 593
- 17.22.4 RECENT DEVELOPMENT 593
17.23 QIAGEN 594
- 17.23.1 COMPANY SNAPSHOT 594
- 17.23.2 REVENUE ANALYSIS 594
- 17.23.3 PRODUCT PORTFOLIO 595
- 17.23.4 RECENT DEVELOPMENT 595
17.24 SORENSON GENOMICS 596
- 17.24.1 COMPANY SNAPSHOT 596
- 17.24.2 PRODUCT PORTFOLIO 596
- 17.24.3 RECENT DEVELOPMENT 596

18 QUESTIONNAIRE 597

19 RELATED REPORTS 600

LIST OF TABLES

TABLE 1 GLOBAL GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 109
TABLE 2 GLOBAL GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 109
TABLE 3 GLOBAL DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 4 GLOBAL PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 110
TABLE 5 GLOBAL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 111
TABLE 6 GLOBAL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UUNITS) 111
TABLE 7 GLOBAL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 111
TABLE 8 GLOBAL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 112
TABLE 9 GLOBAL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 113
TABLE 10 GLOBAL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 115
TABLE 11 GLOBAL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 115
TABLE 12 GLOBAL NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 13 GLOBAL NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 116
TABLE 14 GLOBAL PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 117
TABLE 15 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 118
TABLE 16 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 118
TABLE 17 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 118
TABLE 18 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 119
TABLE 19 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 119
TABLE 20 GLOBAL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 119
TABLE 21 GLOBAL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 120
TABLE 22 GLOBAL CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 120
TABLE 23 GLOBAL OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 121
TABLE 24 GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 126
TABLE 25 GLOBAL POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 126
TABLE 26 GLOBAL POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 127
TABLE 27 GLOBAL DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 128
TABLE 28 GLOBAL DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 128
TABLE 29 GLOBAL WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 129
TABLE 30 GLOBAL MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 129
TABLE 31 GLOBAL MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 130
TABLE 32 GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 130
TABLE 33 GLOBAL OTHERS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 131
TABLE 34 GLOBAL GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 136
TABLE 1 GLOBAL CANCER IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 136
TABLE 2 GLOBAL CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 137
TABLE 3 GLOBAL SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
TABLE 4 GLOBAL THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
TABLE 5 GLOBAL RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 139
TABLE 6 GLOBAL RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 139
TABLE 7 GLOBAL FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 140
TABLE 8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 141
TABLE 9 GLOBAL HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 141
TABLE 10 GLOBAL CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 142
TABLE 11 GLOBAL OTHERS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 142
TABLE 12 GLOBAL GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 147
TABLE 13 GLOBAL HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 147
TABLE 14 GLOBAL CLINICS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 148
TABLE 15 GLOBAL DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 148
TABLE 16 GLOBAL PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 149
TABLE 17 GLOBAL LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 149
TABLE 18 GLOBAL PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 150
TABLE 19 GLOBAL GENETIC TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND) 154
TABLE 20 NORTH AMERICA GENETIC TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 155
TABLE 21 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 155
TABLE 22 NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 156
TABLE 23 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 156
TABLE 24 NORTH AMERICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 156
TABLE 25 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 156
TABLE 26 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 157
TABLE 27 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 157
TABLE 28 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 158
TABLE 29 NORTH AMERICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 158
TABLE 30 NORTH AMERICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 158
TABLE 31 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 159
TABLE 32 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 159
TABLE 33 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 159
TABLE 34 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 159
TABLE 35 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 160
TABLE 36 NORTH AMERICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 160
TABLE 37 NORTH AMERICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 160
TABLE 38 NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 161
TABLE 39 NORTH AMERICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 161
TABLE 40 NORTH AMERICA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 162
TABLE 41 NORTH AMERICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 162
TABLE 42 NORTH AMERICA GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 163
TABLE 43 NORTH AMERICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 163
TABLE 44 NORTH AMERICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 164
TABLE 45 NORTH AMERICA GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 164
TABLE 46 U.S. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 165
TABLE 47 U.S. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 165
TABLE 48 U.S. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 166
TABLE 49 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 166
TABLE 50 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 166
TABLE 51 U.S. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 166
TABLE 52 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 167
TABLE 53 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 167
TABLE 54 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 167
TABLE 55 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 168
TABLE 56 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 168
TABLE 57 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 168
TABLE 58 U.S. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 169
TABLE 59 U.S. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 60 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 61 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 169
TABLE 62 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP) 170
TABLE 63 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 64 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 170
TABLE 65 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 170
TABLE 66 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 67 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 171
TABLE 68 U.S. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 171
TABLE 69 U.S. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 171
TABLE 70 U.S. GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 172
TABLE 71 U.S. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 172
TABLE 72 U.S. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 173
TABLE 73 U.S. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 173
TABLE 74 U.S. GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 174
TABLE 75 U.S. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 174
TABLE 76 U.S. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 175
TABLE 77 U.S. GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 175
TABLE 78 CANADA GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 176
TABLE 79 CANADA GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 176
TABLE 80 CANADA GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 177
TABLE 81 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 177
TABLE 82 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 177
TABLE 83 CANADA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 177
TABLE 84 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 178
TABLE 85 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 178
TABLE 86 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 178
TABLE 87 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 179
TABLE 88 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 179
TABLE 89 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 180
TABLE 90 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 180
TABLE 91 CANADA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 180
TABLE 92 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 93 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 181
TABLE 94 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP) 181
TABLE 95 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 96 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 181
TABLE 97 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 182
TABLE 98 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 99 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 182
TABLE 100 CANADA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 182
TABLE 101 CANADA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 183
TABLE 102 CANADA GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 183
TABLE 103 CANADA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 184
TABLE 104 CANADA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 184
TABLE 105 CANADA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 184
TABLE 106 CANADA GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 185
TABLE 107 CANADA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 185
TABLE 108 CANADA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 186
TABLE 109 CANADA GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 186
TABLE 110 MEXICO GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 187
TABLE 111 MEXICO GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 187
TABLE 112 MEXICO GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 188
TABLE 113 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 114 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 188
TABLE 115 MEXICO PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 188
TABLE 116 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 189
TABLE 117 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 189
TABLE 118 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 189
TABLE 119 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 190
TABLE 120 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 121 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 190
TABLE 122 MEXICO NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 191
TABLE 123 MEXICO NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 191
TABLE 124 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 191
TABLE 125 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 191
TABLE 126 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP) 192
TABLE 127 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 128 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 192
TABLE 129 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 192
TABLE 130 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 131 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 193
TABLE 132 MEXICO EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 193
TABLE 133 MEXICO CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 193
TABLE 134 MEXICO GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 194
TABLE 135 MEXICO POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 194
TABLE 136 MEXICO DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 195
TABLE 137 MEXICO MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 195
TABLE 138 MEXICO GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 196
TABLE 139 MEXICO RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 196
TABLE 140 MEXICO CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 197
TABLE 141 MEXICO GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 197
TABLE 142 EUROPE GENETIC TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 198
TABLE 143 EUROPE GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 144 EUROPE GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 199
TABLE 145 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 199
TABLE 146 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 199
TABLE 147 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 199
TABLE 148 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 200
TABLE 149 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 200
TABLE 150 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 201
TABLE 151 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 201
TABLE 152 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 201
TABLE 153 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 154 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 202
TABLE 155 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 156 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 202
TABLE 157 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 203
TABLE 158 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 203
TABLE 159 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 203
TABLE 160 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 204
TABLE 161 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 204
TABLE 162 EUROPE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 204
TABLE 163 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 205
TABLE 164 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 205
TABLE 165 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 206
TABLE 166 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 206
TABLE 167 EUROPE GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 206
TABLE 168 GERMANY GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 207
TABLE 169 GERMANY GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 207
TABLE 170 GERMANY GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 208
TABLE 171 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 208
TABLE 172 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 208
TABLE 173 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 208
TABLE 174 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 209
TABLE 175 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 209
TABLE 176 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 209
TABLE 177 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 210
TABLE 178 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 179 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 211
TABLE 180 CANADA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 211
TABLE 181 GERMANY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 211
TABLE 182 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 183 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 212
TABLE 184 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP) 212
TABLE 185 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 186 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 213
TABLE 187 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 213
TABLE 188 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 189 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 213
TABLE 190 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 213
TABLE 191 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 214
TABLE 192 GERMANY GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 214
TABLE 193 GERMANY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 215
TABLE 194 GERMANY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 215
TABLE 195 GERMANY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 215
TABLE 196 GERMANY GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 216
TABLE 197 GERMANY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 216
TABLE 198 GERMANY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 217
TABLE 199 GERMANY GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 217
TABLE 200 FRANCE GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 218
TABLE 201 FRANCE GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 218
TABLE 202 FRANCE GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 219
TABLE 203 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 219
TABLE 204 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 219
TABLE 205 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 219
TABLE 206 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 220
TABLE 207 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 220
TABLE 208 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 220
TABLE 209 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 221
TABLE 210 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 221
TABLE 211 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 222
TABLE 212 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 222
TABLE 213 FRANCE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 222
TABLE 214 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 223
TABLE 215 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (UNITS) 223
TABLE 216 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP) 223
TABLE 217 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 223
TABLE 218 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 223
TABLE 219 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 224
TABLE 220 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 221 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 224
TABLE 222 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 224
TABLE 223 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2022-2031 (USD THOUSAND) 225
TABLE 224 FRANCE GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 225
TABLE 225 FRANCE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 226
TABLE 226 FRANCE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 226
TABLE 227 FRANCE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND) 226
TABLE 228 FRANCE GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 227
TABLE 229 FRANCE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 227
TABLE 230 FRANCE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2022-2031 (USD THOUSAND) 228
TABLE 231 FRANCE GENETIC TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND) 228
TABLE 232 U.K. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 229
TABLE 233 U.K. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 229
TABLE 234 U.K. GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 230
TABLE 235 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 236 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (UNITS) 230
TABLE 237 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (ASP) 230
TABLE 238 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (USD THOUSAND) 231
TABLE 239 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (UNITS) 231
TABLE 240 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2022-2031 (ASP) 231
TABLE 241 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2022-2031 (USD THOUSAND) 232
TABLE 242 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 243 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (UNITS) 232
TABLE 244 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2022-2031 (ASP) 233
TABLE 245 U.K. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 233
TABLE 246 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 233

LIST OF FIGURES

FIGURE 1 GLOBAL GENETIC TESTING MARKET: SEGMENTATION 73
FIGURE 2 GLOBAL GENETIC TESTING MARKET: DATA TRIANGULATION 76
FIGURE 3 GLOBAL GENETIC TESTING MARKET: DROC ANALYSIS 77
FIGURE 4 GLOBAL GENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 78
FIGURE 5 GLOBAL GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS 78
FIGURE 6 MULTIVARIATE MODELLING 79
FIGURE 7 GLOBAL GENETIC TESTING MARKET: DBMR MARKET POSITION GRID 82
FIGURE 8 GLOBAL GENETIC TESTING MARKET: APPLICATION COVERAGE GRID 83
FIGURE 9 GLOBAL GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS 84
FIGURE 10 GLOBAL GENETIC TESTING MARKET: SEGMENTATION 87
FIGURE 11 INCREASING PREVALENCE OF GENETIC DISORDERS ARE EXPECTED TO DRIVE THE GLOBAL GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 88
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GENETIC TESTING MARKET IN 2024 & 2031 88
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031 89
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR GENETIC TESTING MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031 90
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL GENETIC TESTING MARKET 97
FIGURE 16 GLOBAL GENETIC TESTING MARKET: BY TYPE, 2023 106
FIGURE 17 GLOBAL GENETIC TESTING MARKET: BY TYPE, 2024-2031 (USD THOUSAND) 107
FIGURE 18 GLOBAL GENETIC TESTING MARKET: BY TYPE, CAGR (2024-2031) 107
FIGURE 19 GLOBAL GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE 108
FIGURE 20 GLOBAL GENETIC TESTING MARKET: BY TECHNOLOGY, 2023 123
FIGURE 21 GLOBAL GENETIC TESTING MARKET: BY TECHNOLOGY, 2024-2031 (USD THOUSAND) 124
FIGURE 22 GLOBAL GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2024-2031) 124
FIGURE 23 GLOBAL GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE 125
FIGURE 24 GLOBAL GENETIC TESTING MARKET: BY DISEASES, 2023 133
FIGURE 25 GLOBAL GENETIC TESTING MARKET: BY DISEASES, 2023-2031 (USD THOUSAND) 134
FIGURE 26 GLOBAL GENETIC TESTING MARKET: BY DISEASES, CAGR (2023-2031) 134
FIGURE 27 GLOBAL GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE 135
FIGURE 28 GLOBAL GENETIC TESTING MARKET: BY END USER, 2023 144
FIGURE 29 GLOBAL GENETIC TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND) 145
FIGURE 30 GLOBAL GENETIC TESTING MARKET: BY END USER, CAGR (2024-2031) 145
FIGURE 31 GLOBAL GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE 146
FIGURE 32 GLOBAL GENETIC TESTING MARKET: SNAPSHOT (2023) 153
FIGURE 33 GLOBAL GENETIC TESTING MARKET: COMPANY SHARE 2023 (%) 544
FIGURE 34 NORTH AMERICA GENETIC TESTING MARKET: COMPANY SHARE 2023 (%) 545
FIGURE 35 EUROPE GENETIC TESTING MARKET: COMPANY SHARE 2023 (%) 546
FIGURE 36 ASIA-PACIFIC GENETIC TESTING MARKET: COMPANY SHARE 2023 (%) 547